Allogene Therapeutics, Inc. (ALLO)

NASDAQ: ALLO · IEX Real-Time Price · USD
14.81
-0.55 (-3.58%)
At close: Aug 19, 2022 4:00 PM
15.16
+0.35 (2.36%)
After-hours: Aug 19, 2022 4:21 PM EDT

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year 2021202020192018
Revenue
38.49000
Gross Profit
38.49000
Selling, General & Admin
74.1165.2657.4740.98
Research & Development
220.18192.99144.54151.86
Operating Expenses
294.28258.24202.01192.84
Operating Income
-255.79-258.24-202.01-192.84
Interest Expense / Income
0003.36
Other Expense / Income
1.21-8.02-17.0815.42
Pretax Income
-257.01-250.22-184.93-211.62
Income Tax
00-0.33-0.12
Net Income
-257.01-250.22-184.59-211.51
Net Income Common
-257.01-250.22-184.59-211.51
Shares Outstanding (Basic)
13612010129
Shares Outstanding (Diluted)
13612010129
Shares Change
12.84%19.11%249.11%-
EPS (Basic)
-1.89-2.08-1.83-7.31
EPS (Diluted)
-1.89-2.08-1.83-7.31
Free Cash Flow Per Share
-1.52-1.50-1.86-1.65
Gross Margin
100.00%---
Operating Margin
-664.60%---
Profit Margin
-667.70%---
Free Cash Flow Margin
-535.90%---
Effective Tax Rate
0.00%0.00%0.18%0.06%
EBITDA
-246.55-242.79-180.5-207.22
EBITDA Margin
-640.60%---
Depreciation & Amortization
10.457.444.421.05
EBIT
-257.01-250.22-184.93-208.26
EBIT Margin
-667.70%---
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).